Monoclonal antibodies and fragment thereof directed against the human anti-mullerian hormone type ii receptor (amhr-ii)
AssigneeInstitut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsIsabelle Teulon, André Pelegrin
Life of this patent
Estimating the term…
Abstract
The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers.
Claims20
1-6. (canceled)
A monoclonal antibody having specificity for human Anti-Müllerian Hormone type II receptor (AMHR-II) which comprises:
- (a) a heavy chain which comprises SEQ ID NO:
- 2 for CDR-1, SEQ ID NO:
- 3 for CDR-2 and SEQ ID No:
- 4 for CDR-3;
- and
- (b) a light chain which comprises SEQ ID NO:
- 6 for CDR-1, SEQ ID NO:
- 7 for CDR-2 and SEQ ID NO:
- 8 for CDR-3.
A fragment of a monoclonal antibody, wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-II) and comprises:
- (a) a heavy chain which comprises SEQ ID NO:
- 2 for CDR-1, SEQ ID NO:
- 3 for CDR-2 and SEQ ID No:
- 4 for CDR-3;
- and
- (b) a light chain which comprises SEQ ID NO:
- 6 for CDR-1, SEQ ID NO:
- 7 for CDR-2 and SEQ ID NO:
- 8 for CDR-3,
- wherein the fragment is selected in the group consisting of Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2 and diabodies fragments.
(canceled)
A nucleic acid comprising a sequence encoding a monoclonal antibody, or a fragment of a monoclonal antibody;
- wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-II) and comprises:
- (a) a heavy chain which comprises SEQ ID NO:
- 2 for CDR-1, SEQ ID NO:
- 3 for CDR-2 and SEQ ID No:
- 4 for CDR-3;
- and
- (b) a light chain which comprises SEQ ID NO:
- 6 for CDR-1, SEQ ID NO:
- 7 for CDR-2 and SEQ ID NO:
- 8 for CDR-3.
A vector comprising a nucleic acid comprising a sequence encoding a monoclonal antibody or a fragment of a monoclonal antibody;
- wherein the antibody is specific for human Müllerian Hormone type II receptor (AMHR-II) and comprises:
- (a) a heavy chain which comprises SEQ ID NO:
- 2 for CDR-1, SEQ ID NO:
- 3 for CDR-2 and SEQ ID No:
- 4 for CDR-3;
- and
- (b) a light chain which comprises SEQ ID NO:
- 6 for CDR-1, SEQ ID NO:
- 7 for CDR-2 and SEQ ID NO:
- 8 for CDR-3.
A host cell, which has been transformed by a nucleic acid comprising a sequence encoding a monoclonal antibody or a fragment of a monoclonal antibody, and/or a vector comprising a nucleic acid comprising a sequence encoding a monoclonal antibody, or a fragment of a monoclonal antibody;
- wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-II) and comprises:
- (a) a heavy chain which comprises SEQ ID NO:
- 2 for CDR-1, SEQ ID NO:
- 3 for CDR-2 and SEQ ID No:
- 4 for CDR-3;
- and
- (b) a light chain which comprises SEQ ID NO:
- 6 for CDR-1, SEQ ID NO:
- 7 for CDR-2 and SEQ ID NO:
- 8 for CDR-3.
A method of producing an antibody, or a fragment of an antibody, wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-II) and comprises:
- (a) a heavy chain which comprises SEQ ID NO:
- 2 for CDR-1, SEQ ID NO:
- 3 for CDR-2 and SEQ ID No:
- 4 for CDR-3;
- and
- (b) a light chain which comprises SEQ ID NO:
- 6 for CDR-1, SEQ ID NO:
- 7 for CDR-2 and SEQ ID NO:
- 8 for CDR-3;
- which method comprises the steps consisting of:
- (i) culturing, under conditions suitable to allow expression of said antibody, a host cell which has been transformed by a nucleic acid comprising a sequence encoding a monoclonal antibody or a fragment of a monoclonal antibody, and/or a vector comprising a nucleic acid comprising a sequence encoding a monoclonal antibody or a fragment of a monoclonal antibody;
- wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-II) and comprises:
- (a) a heavy chain which comprises SEQ ID NO:
- 2 for CDR-1, SEQ ID NO:
- 3 for CDR-2 and SEQ ID No:
- 4 for CDR-3;
- and
- (b) a light chain which comprises SEQ ID NO:
- 6 for CDR-1, SEQ ID NO:
- 7 for CDR-2 and SEQ ID NO:
- 8 for CDR-3;
- and
- (ii) recovering the expressed antibody.
A pharmaceutical composition comprising
- an antibody,
- and/or a fragment of an antibody,
- or a nucleic acid comprising a sequence encoding a monoclonal antibody or a fragment of a monoclonal antibody,
- and/or a vector comprising a nucleic acid comprising a sequence encoding a monoclonal antibody or a fragment of a monoclonal antibody,
- and/or a host cell a host cell which has been transformed by a nucleic acid comprising a sequence encoding a monoclonal antibody or a fragment of a monoclonal antibody, and/or a vector comprising a nucleic acid comprising a sequence encoding a monoclonal antibody or a fragment of a monoclonal antibody;
- together with a pharmaceutically acceptable carrier;
- wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-II) and comprises:
- (a) a heavy chain which comprises SEQ ID NO:
- 2 for CDR-1, SEQ ID NO:
- 3 for CDR-2 and SEQ ID No:
- 4 for CDR-3;
- and
- (b) a light chain which comprises SEQ ID NO:
- 6 for CDR-1, SEQ ID NO:
- 7 for CDR-2 and SEQ ID NO:
- 8 for CDR-3.
An immunoconjugate comprising an antibody, or a fragment of an antibody, wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-II) and comprises:
- (a) a heavy chain which comprises SEQ ID NO:
- 2 for CDR-1, SEQ ID NO:
- 3 for CDR-2 and SEQ ID No:
- 4 for CDR-3;
- and
- (b) a light chain which comprises SEQ ID NO:
- 6 for CDR-1, SEQ ID NO:
- 7 for CDR-2 and SEQ ID NO:
- 8 for CDR-3;
- conjugated to an anti-cancer agent.
A method for treating an ovarian cancer comprising administering a subject in need thereof with a therapeutically effective amount of an antibody, or a fragment of an antibody, or an immunoconjugate comprising an antibody or a fragment of an antibody conjugated to an anticancer agent,
- wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-II) and comprises:
- (a) a heavy chain which comprises SEQ ID NO:
- 2 for CDR-1, SEQ ID NO:
- 3 for CDR-2 and SEQ ID No:
- 4 for CDR-3;
- and
- (b) a light chain which comprises SEQ ID NO:
- 6 for CDR-1, SEQ ID NO:
- 7 for CDR-2 and SEQ ID NO:
- 8 for CDR-3.
A method of diagnosing and/or monitoring an ovarian cancer in a subject, comprising the steps of:
- (i) contacting a biological sample of a subject likely to suffer from an ovarian cancer with an antibody, or a fragment of an antibody, wherein the antibody is specific for human Anti-Müllerian Hormone type II receptor (AMHR-II) and comprises:
- (a) a heavy chain which comprises SEQ ID NO:
- 2 for CDR-1, SEQ ID NO:
- 3 for CDR-2 and SEQ ID No:
- 4 for CDR-3;
- and
- (b) a light chain which comprises SEQ ID NO:
- 6 for CDR-1, SEQ ID NO:
- 7 for CDR-2 and SEQ ID NO:
- 8 for CDR-3,
- in conditions sufficient for the antibody or the fragment of antibody to form complexes with cells of the biological sample that express AMHR-II and
- (ii) detecting and/or quantifying said complexes;
- whereby the detection of said complexes is indicative of an ovarian cancer.
Dependencies are inferred from the claim text.